An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia
Key facts
- Who runs it
- H. Lundbeck A/S
- Where
- Sweden2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 45 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 31 Jul 2031
- Type of study
- Interventional
- Treatments tested
- Asedebart
- Record updated
- 5 October 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- The participant has been treated with asedebart in a clinical trial
- The participant had an acceptable benefit-risk assessment in the prior trial and would benefit from continued treatment with asedebart in the opinion of the investigator
- For participants with > 12 weeks since their last dose of asedebart: The participant has been on a stable daily dose of GC replacement therapy of ≥ 8 milligram per square meter (mg/m\^2) (adjusted for body surface area in hydrocortisone equivalent dosage [HCe]) for >= 1 month prior to the Screening Visit
- For participants with > 12 weeks since their last dose of asedebart: The participant is not adequately controlled on their current treatment and, at the Screening/Baseline Visit, has either:; elevated androgen blood concentrations (A4 > upper limit of normal (ULN) for age and sex) in morning measurements (pre-GC replacement dose) OR; androgen blood concentrations within the reference range (A4 <= ULN for age and sex) and is being treated with supraphysiological GC (GC daily dose > 13 mg/m\^2 adjusted for body surface area in HCe)
Who cannot take part
- The participant has taken any investigational medicinal product (IMP) other than asedebart < 3 months or < 5 half-lives, whichever is longer, prior to the first dose of asedebart in this trial
- The participant has known hypersensitivity or intolerance to asedebart or its excipients
- The participant has an increased risk of adrenal crisis in the opinion of the investigator (for example history of repeated adrenal crisis in recent years, history of adrenal crisis caused by reduction of GC dose); Other protocol-defined criteria apply
- The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main goal of the trial is to study the long-term safety, how well people can handle the treatment, and how asedebart acts in the body and affects the body when used to treat classic congenital adrenal hyperplasia (CAH). The trial will include participants who have previously received asedebart in trial 19873A (NCT05669950).
The group in the trial
- AsedebartTreatment being tested
Participants will receive asedebart per a prespecified dosing schedule.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Interventional, Open-label, Extension Trial of Asedebart (Lu AG13909) in Participants With Congenital Adrenal Hyperplasia
- Criteria questions
- Built from NCT07859293, who can take part
- Record updated
- 5 October 2026